Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug–Drug Interactions
Opioids are commonly prescribed for the treatment of chronic pain. Approximately 50% of adults who are prescribed opioids for pain co-use cannabis with their opioid treatment. Morphine is primarily metabolized by UDP-glucuronosyltransferase (UGT) 2B7 to an inactive metabolite, morphine-3-glucuronide...
Main Authors: | Shelby Coates, Keti Bardhi, Philip Lazarus |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/16/3/418 |
Similar Items
-
Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid–Oxazepam Drug Interactions
by: Keti Bardhi, et al.
Published: (2024-02-01) -
Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats
by: Agnieszka Karbownik, et al.
Published: (2021-12-01) -
Cannabinoids in nature and medicine /
by: Lambert, Didier M.
Published: (2009) -
Glucuronidation Pathways of 5- and 7-Hydroxypropranolol: Determination of Glucuronide Structures and Enzyme Selectivity
by: Fan Yang, et al.
Published: (2023-11-01) -
Microinjection of WIN55,212-2 as a Cannabinoid Agonist into the Basolateral Amygdala Induces Sensitization to Morphine in Rats
by: Marzieh Molaei, et al.
Published: (2014-11-01)